Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Abstract

Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC₅₀) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC₅₀ values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC₅₀ values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC₅₀ values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n=3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.

• Authors: Clyde Dapat, Hiroki Kondo, Isolde C Dapat, Tatiana Baranovich, Yasushi Suzuki, Yugo Shobugawa, Kousuke Saito, Reiko Saito, Hiroshi Suzuki
• Journal: Antiviral research (Antiviral Res) Vol. 99 Issue 3 Pg. 261-9 (Sep 2013) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 23791870 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Acids, Carbocyclic
• Antiviral Agents
• Cyclopentanes
• Enzyme Inhibitors
• Guanidines
• Pyrans
• Sialic Acids
• Viral Proteins
• laninamivir
• NA protein, influenza A virus
• Neuraminidase
• Zanamivir
• peramivir

Topics

• Acids, Carbocyclic
• Adult
• Antiviral Agents (pharmacology)
• Cyclopentanes (pharmacology)
• Drug Resistance, Viral
• Enzyme Inhibitors (pharmacology)
• Female
• Guanidines (pharmacology)
• Humans
• Influenza A Virus, H1N1 Subtype (drug effects, enzymology, genetics, isolation & purification)
• Influenza A Virus, H3N2 Subtype (drug effects, enzymology, genetics, isolation & purification)
• Influenza B virus (drug effects, enzymology, genetics, isolation & purification)
• Influenza, Human (epidemiology, virology)
• Japan (epidemiology)
• Microbial Sensitivity Tests
• Neuraminidase (antagonists & inhibitors, genetics, metabolism)
• Pandemics
• Pyrans
• Seasons
• Sialic Acids
• Viral Proteins (antagonists & inhibitors, genetics, metabolism)
• Zanamivir (analogs & derivatives, pharmacology)